Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review

Nature Reviews Clinical Oncology volume 16, pages 139–141 (2019)Cite this article

Subjects

In 2018, the FDA approved 19 new drug and biologic applications, 38 supplemental drug and biologic applications and 4 biosimilar applications in oncology. These advances in anticancer therapy included a landmark approval of the first histology-agnostic, biomarker-defined new molecular entity and approvals based on real-time data review and novel end points, such as minimal residual disease rate and metastasis-free survival.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: FDA haematology–oncology (cancer) drug approvals in 2018.

References

  1. Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).

    Article  CAS  Google Scholar 

  2. US Food and Drug Administration. Expansion cohorts: use in first-in-human clinical trials to expedite development of oncology drugs and biologics. FDA https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM616325.pdf (2018).

  3. US Food and Drug Administration. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics. FDA https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM621817.pdf (2018).

  4. Blumenthal, G. M. & Pazdur, R. Approvals in 2017: gene therapies and site-agnostic indications. Nat. Rev. Clin. Oncol. 15, 127–128 (2018).

    Article  Google Scholar 

  5. Beaver, J. A., Kluetz, P. F. & Pazdur, R. Metastasis-free survival — a new end point in prostate cancer trials. N. Engl. J. Med. 378, 2458–2460 (2018).

    Article  Google Scholar 

  6. US Food & Drug Administration. Nonmetastatic, castration-resistant prostate cancer: considerations for metastasis-free survival endpoint in clinical trials. FDA https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM625703.pdf (2018).

  7. US Food & Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics. FDA https://www.fda.gov/downloads/drugsGuidanceComplianceRegulatoyInformation/Guidance/UCM071590.pdf (2018).

  8. US Food & Drug Administration. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment. FDA https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM623333.pdf (2018).

  9. US Food & Drug Administration. FDA alerts health care professionals and oncology clinical investigators about an efficacy issue identified in clinical trials for some patients taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as monotherapy to treat urothelial cancer with low expression of PD-L1. FDA https://www.fda.gov/Drugs/DrugSafety/ucm608075.htm (2018).

  10. Gormley, N. J. & Pazdur, R. Immunotherapy combinations in multiple myeloma — known unknowns. N. Engl. J. Med. 379, 1791–1795 (2018).

    Article  Google Scholar 

  11. Blumenthal, G. M. et al. Real-time oncology review and the assessment aid: increasing review efficiency through standardization and earlier data access. Friends of Cancer Research https://www.focr.org/sites/default/files/ROTR%20White%20Paper%201.pdf (2018).

  12. Sutter, S. Project renewal: US FDA’s plan to update generic cancer drug labels depends on NDA holders. Pink Sheet Pharma intelligence https://pink.pharmaintelligence.informa.com/PS124262/Project-Renewal-US-FDAs-Plan-To-Update-Generic-Cancer-Drug-Labels-Depends-On-NDA-Holders (2018).

  13. Usdin, S. FDA to facilitate access to unapproved drugs. BioCentury https://www.biocentury.com/biocentury/regulation/2018-12-14/how-fda-plans-help-patients-get-expanded-access-unapproved-drugs (2018).

Download references

Acknowledgements

The authors thank K. Goldberg for her assistance in editing this manuscript.

Author information

Authors and Affiliations

  1. Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA

    Gideon M. Blumenthal & Richard Pazdur

Authors
  1. Gideon M. Blumenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Pazdur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gideon M. Blumenthal.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blumenthal, G.M., Pazdur, R. Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review. Nat Rev Clin Oncol 16, 139–141 (2019). https://doi.org/10.1038/s41571-019-0170-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-019-0170-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer